Diabetes & vascular disease research最新文献_第2页

Comparative effectiveness of tirzepatide and DPP-4 inhibitors in type 2 diabetes with heart failure. 替西肽和DPP-4抑制剂治疗2型糖尿病合并心力衰竭的比较疗效。

IF 3

Diabetes & vascular disease research Pub Date : 2026-07-01 Epub Date: 2026-07-08 DOI: 10.1177/14791641261467888

Ibrahim Mortada, Krishna Paul, Michael Chammany, Youstina Abraham, Karthik Devulapally, Aaron W Lee, Shareef Mansour, Khaled Chatila, Michael C Boyars, Dietrich Jehle, Thomas A Blackwell, Hani Jneid

{"title":"Comparative effectiveness of tirzepatide and DPP-4 inhibitors in type 2 diabetes with heart failure.","authors":"Ibrahim Mortada, Krishna Paul, Michael Chammany, Youstina Abraham, Karthik Devulapally, Aaron W Lee, Shareef Mansour, Khaled Chatila, Michael C Boyars, Dietrich Jehle, Thomas A Blackwell, Hani Jneid","doi":"10.1177/14791641261467888","DOIUrl":"10.1177/14791641261467888","url":null,"abstract":"While patients with type 2 diabetes mellitus (T2DM) and heart failure (HF) are frequently prescribed dipeptidyl peptidase-4 inhibitors (DPP-4is), emerging evidence suggests glucagon-like peptide-1 receptor agonists may offer improved outcomes. This study compared the effectiveness of tirzepatide versus DPP-4i in patients with T2DM and HF. Adults with T2DM and HF treated between 2022 and 2025 were included. Cohort A comprised patients receiving tirzepatide, and Cohort B comprised patients receiving DPP-4is. Prespecified subgroup analyses were conducted for HF with reduced ejection fraction (HFrEF) and HF with non-reduced ejection fraction (HFnonrEF). Propensity score matching was performed across demographic, clinical, medication, and laboratory covariates. Outcomes included all-cause mortality, hospitalization, HF exacerbation, and major adverse cardiovascular events (MACE). After matching, 8,956 patients were included in each group. Tirzepatide therapy was associated with a lower hazard of all-cause mortality (HR 0.32, 95% CI 0.25-0.42), hospitalizations (HR 0.53, 95% CI 0.48-0.57), HF exacerbation (HR 0.37, 95% CI 0.33-0.42) and MACE (HR 0.79, 95% CI 0.73-0.84). Sub-group analyses for HFrEF and HFnonrEF demonstrated similar trends. In conclusion, among patients with T2DM and HF, treatment with tirzepatide was associated with markedly lower hazards of mortality, hospitalization, HF exacerbation, and MACE compared to DPP-4 inhibitors.","PeriodicalId":93978,"journal":{"name":"Diabetes & vascular disease research","volume":"23 4","pages":"14791641261467888"},"PeriodicalIF":3.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13346706/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148414136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The expanding role of peptides in cardiovascular care. 肽在心血管护理中的扩展作用。

IF 3

Diabetes & vascular disease research Pub Date : 2026-07-01 Epub Date: 2026-08-06 DOI: 10.1177/14791641261476328

Ana F Pabón Romero, Claudia Martínez

{"title":"The expanding role of peptides in cardiovascular care.","authors":"Ana F Pabón Romero, Claudia Martínez","doi":"10.1177/14791641261476328","DOIUrl":"10.1177/14791641261476328","url":null,"abstract":"Peptides have emerged as key regulators of cardiovascular physiology and increasingly important tools in the diagnosis and management of cardiovascular disease (CVD). Endogenous peptide systems, including natriuretic peptides (NPs), the renin angiotensin system (RAS), and vasopressin, play central roles in maintaining vascular tone, fluid balance, and cardiac remodeling, while their dysregulation contributes to disease progression. Clinically, peptide-based biomarkers such as NPs and copeptin are widely used for diagnosis, risk stratification, and prognostic assessment. Beyond their diagnostic utility, peptides have gained significant attention as therapeutic targets. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated cardiometabolic benefits, including reductions in cardiovascular events and improvements in metabolic profiles. In parallel, advances in peptide engineering have enabled the development of innovative therapeutic strategies, including targeted drug delivery systems, regenerative therapies, and enzyme-responsive biomaterials designed to enhance myocardial repair. This review provides a comprehensive overview of the biological, diagnostic, and therapeutic roles of peptides in cardiovascular medicine. Collectively, these findings highlight the expanding clinical relevance of peptides and their potential to support precision-based approaches in cardiovascular care.","PeriodicalId":93978,"journal":{"name":"Diabetes & vascular disease research","volume":"23 4","pages":"14791641261476328"},"PeriodicalIF":3.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13451712/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148681481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The correlation between impaired thyroid hormone sensitivity and 10-year atherosclerotic cardiovascular disease (ASCVD) risk score in patients with type 2 diabetes mellitus. 2型糖尿病患者甲状腺激素敏感性受损与10年动脉粥样硬化性心血管疾病（ASCVD）风险评分的相关性

IF 3

Diabetes & vascular disease research Pub Date : 2026-07-01 Epub Date: 2026-08-28 DOI: 10.1177/14791641261484963

Yuqian Zhang, Juan Wang, Huaner Wang, Yefan Yang, Junni Zhu, Lihua Ma, Jingfang Liu

{"title":"The correlation between impaired thyroid hormone sensitivity and 10-year atherosclerotic cardiovascular disease (ASCVD) risk score in patients with type 2 diabetes mellitus.","authors":"Yuqian Zhang, Juan Wang, Huaner Wang, Yefan Yang, Junni Zhu, Lihua Ma, Jingfang Liu","doi":"10.1177/14791641261484963","DOIUrl":"10.1177/14791641261484963","url":null,"abstract":"BackgroundAtherosclerotic cardiovascular disease (ASCVD) is one of the common complications in patients with type 2 diabetes mellitus (T2DM). Thyroid hormones affect cardiovascular function through multiple pathways.PurposeTo explore the relationships between impaired thyroid hormone sensitivity and the 10-year risk of ASCVD in euthyroid patients with T2DM.Methods899 patients with T2DM were divided into three groups according to the different ASCVD risk levels, the difference of thyroid hormone sensitivity indices [Parametric Thyroid Feedback Quantile-based Index (PTFQI), Thyroid Feedback Quantile-based Index (TFQI), Thyroid Stimulating Hormone Index (TSHI), Serum-Free triiodothyronine to Free thyroxine (FT3/FT4) ratio, and Thyrotropin Thyroxine Resistance Index (TT4RI)] between three groups were compared.ResultsAs the 10-year ASCVD risk grade increased, TT4RI level showed a gradually rising trend, while FT3/FT4 ratio exhibited a decreasing trend (P < 0.05). PTFQI, TFQI, TSHI, and TT4RI were positively, and FT3/FT4 was negatively correlated with ASCVD risk (all P < 0.05). Thyroid hormone sensitivity indicators had a linear dose-response relationships with ASCVD risk. As the levels of PTFQI, TFQI, TSHI, and TT4RI increase and the level of FT3/FT4 decreases, the ASCVD risk showed an upward trend.ConclusionTo patients with T2DM, impaired thyroid hormone sensitivity is associated with ASCVD risk.","PeriodicalId":93978,"journal":{"name":"Diabetes & vascular disease research","volume":"23 4","pages":"14791641261484963"},"PeriodicalIF":3.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13525252/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148852105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Body composition rather than liver fat associates with carotid Intima-Media thickness in youth with type 1 diabetes. 1型糖尿病青年患者颈动脉内膜-中膜厚度与身体成分而非肝脏脂肪有关。

IF 3

Diabetes & vascular disease research Pub Date : 2026-07-01 Epub Date: 2026-07-15 DOI: 10.1177/14791641261470422

Emir Tas, Memduha Gumus, Swetha Movva, Brenda Mendizabal, Emma Barinas-Mitchell, Zhenwei Gong, Jonathan A Dranoff, Radhika Muzumdar, Ingrid Libman

{"title":"Body composition rather than liver fat associates with carotid Intima-Media thickness in youth with type 1 diabetes.","authors":"Emir Tas, Memduha Gumus, Swetha Movva, Brenda Mendizabal, Emma Barinas-Mitchell, Zhenwei Gong, Jonathan A Dranoff, Radhika Muzumdar, Ingrid Libman","doi":"10.1177/14791641261470422","DOIUrl":"10.1177/14791641261470422","url":null,"abstract":"IntroductionMetabolic dysfunction-associated steatotic liver disease (MASLD) is a recognized cardiometabolic risk factor in adults, but its relevance to early vascular remodeling in youth with type 1 diabetes (T1D) remains unclear. We evaluated the independent associations of hepatic fat and body composition with early structural vascular remodeling in youth with T1D.MethodsThis cross-sectional study included 49 late-pubertal youth with T1D (mean age 16.1±2.6 years; duration 7.5±4.3 years). Hepatic fat was quantified using MRI-proton density fat fraction (PDFF), while body composition and estimated insulin sensitivity (eIS) were assessed using dual-energy X-ray absorptiometry and a validated pediatric equation. Carotid intima-media thickness (cIMT), measured by ultrasound, served as the primary outcome. Hierarchical linear regression assessed independent associations after adjustment for age, sex, and diabetes duration.ResultsMean hepatic fat was 1.87±1.22%, with no participants meeting criteria for steatosis. Hepatic fat, eIS, and diabetes duration were not associated with cIMT. Lean body mass was the primary independent associate of cIMT (β=0.44, p=0.02). Although eIS was strongly associated with waist circumference (r=-0.76, p<0.001), neither variable was associated with cIMT.ConclusionsIn this sub-steatotic cohort, cIMT was primarily associated with lean body mass, reflecting physiologic growth, while central adiposity was associated with metabolic dysfunction but not vascular structure.","PeriodicalId":93978,"journal":{"name":"Diabetes & vascular disease research","volume":"23 4","pages":"14791641261470422"},"PeriodicalIF":3.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13373370/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148450968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

MiR-143-3p serves as a novel biomarker for diabetic cardiomyopathy and is involved in regulating high glucose-induced cardiomyocyte injury. MiR-143-3p作为糖尿病心肌病的一种新的生物标志物，参与调节高糖诱导的心肌细胞损伤。

IF 3

Diabetes & vascular disease research Pub Date : 2026-07-01 Epub Date: 2026-07-22 DOI: 10.1177/14791641261454501

Zhengnan Zhang, Suyun Wang, Liping Zhu, Yang Bian, Jing Zhao

{"title":"MiR-143-3p serves as a novel biomarker for diabetic cardiomyopathy and is involved in regulating high glucose-induced cardiomyocyte injury.","authors":"Zhengnan Zhang, Suyun Wang, Liping Zhu, Yang Bian, Jing Zhao","doi":"10.1177/14791641261454501","DOIUrl":"10.1177/14791641261454501","url":null,"abstract":"ObjectiveThis work aimed to verify the value of miR-143-3p in diabetic cardiomyopathy (DCM).MethodsThe ROC curve, correlation analysis, and multivariate Logistic regression analysis assessed the diagnostic value, association with DCM, and DCM risk factors. Bioinformatic analysis predicted the downstream targets of miR-143-3p. Dula-luciferase reporter assay validated the interaction between miR-143-3p and ERBB3. In vitro high glucose (HG)-stimulated cardiomyocyte (AC16) injury was employed to clarify the mechanism of the miR-143-3p/ERBB3 axis in DCM.ResultsUpregulation of miR-143-3p was observed in the DM group and further elevated in the DCM group compared with healthy individuals. The upregulated miR-143-3p expression distinguished subjects with DM from healthy individuals and diagnosed subjects with DCM from DM. MiR-143-3p expression was associated with blood glucose, myocardial injury, and cardiac function of DCM, and predicted the risk for DCM development. In vitro, the inhibition of miR-143-3p attenuated HG-induced AC16 cell injury through improving cell proliferation, suppressing apoptosis, inflammation, oxidative stress, and the release of myocardial enzymes by upregulating the ERBB3 expression.ConclusionsUpregulation of miR-143-3p showed a diagnostic potential for DCM and predicted the progression of DCM. In vitro, miR-143-3p promoted HG-induced cardiomyocyte injury by targeting ERBB3, which might provide novel insights for DCM clinical management.","PeriodicalId":93978,"journal":{"name":"Diabetes & vascular disease research","volume":"23 4","pages":"14791641261454501"},"PeriodicalIF":3.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13392317/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148551758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sensory testing in type 2 diabetes: Insights into neuropathy and systemic complications. 2型糖尿病的感觉测试：对神经病变和全身并发症的见解。

IF 3

Diabetes & vascular disease research Pub Date : 2026-07-01 Epub Date: 2026-07-23 DOI: 10.1177/14791641261472406

Sinem Başak Tan Öksüz, Emine Selin Yıldırım, Atilla Halil Elhan, Rıfat Emral, Mustafa Şahin

{"title":"Sensory testing in type 2 diabetes: Insights into neuropathy and systemic complications.","authors":"Sinem Başak Tan Öksüz, Emine Selin Yıldırım, Atilla Halil Elhan, Rıfat Emral, Mustafa Şahin","doi":"10.1177/14791641261472406","DOIUrl":"10.1177/14791641261472406","url":null,"abstract":"AimsSensory tests such as vibration perception threshold (VPT), monofilament, pinprick, and temperature sensation are used to detect diabetic peripheral neuropathy (DPN). This study examined associations between these tests and chronic diabetic complications in type 2 diabetes, focusing on the clinical relevance of VPT.MethodsIn this retrospective study, 652 patients with type 2 diabetes evaluated at a tertiary center (2014-2024) underwent standardized neurological assessments. Based on VPT, patients were categorized as normal (<16 V), borderline (16-24 V), or abnormal (≥25 V). Associations between sensory tests and retinopathy, nephropathy, ischemic heart disease (IHD), cerebrovascular disease (CeVD), and diabetic foot ulcer (DFU) were examined in cross-sectional and longitudinal analyses.ResultsAbnormal VPT was present in 31.3% of patients and was independently associated with all five complications after multivariable adjustment: IHD (OR: 2.15), CeVD (OR: 3.31), DFU (OR: 15.94), retinopathy (OR: 7.66), and nephropathy (OR: 2.56). Borderline VPT was also independently associated with several outcomes. In a longitudinal subset (n=221; median follow-up ∼5 years), abnormal VPT was associated with incident IHD, DFU, retinopathy, and nephropathy.ConclusionVPT showed strong associations with microvascular and macrovascular complications, supporting its role as a practical indicator of systemic disease burden in type 2 diabetes.","PeriodicalId":93978,"journal":{"name":"Diabetes & vascular disease research","volume":"23 4","pages":"14791641261472406"},"PeriodicalIF":3.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13396539/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148581743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of ceramides in the pathophysiology of diabetic retinopathy: Mechanisms and Implications for therapeutic strategies. 神经酰胺在糖尿病视网膜病变病理生理中的作用：机制和治疗策略的意义。

IF 3

Diabetes & vascular disease research Pub Date : 2026-07-01 Epub Date: 2026-08-04 DOI: 10.1177/14791641261474007

Xiaoji Niu, Yiwei Huang, Chao Sun, Yan Huo, Kanghua Fu, Shishuang Yu, Tianyuan Wang, Jiajia Liu, Weirong Pu, Jinping Hu, Liman Ren

引用次数: 0

Analysis of the diabetic arterial transcriptome to define novel biomarkers of macrovascular disease. 分析糖尿病动脉转录组以确定大血管疾病的新生物标志物。

IF 3

Diabetes & vascular disease research Pub Date : 2026-07-01 Epub Date: 2026-08-01 DOI: 10.1177/14791641261474099

Aya Shouma, Marilena Giannoudi, Marcella Conning-Rowland, Michael Drozd, Oliver I Brown, Chew Cheng, Piruthivi Sukumar, Katherine I Bridge, Eylem Levelt, Marc A Bailey, Kathryn J Griffin, Mark T Kearney, Richard M Cubbon

{"title":"Analysis of the diabetic arterial transcriptome to define novel biomarkers of macrovascular disease.","authors":"Aya Shouma, Marilena Giannoudi, Marcella Conning-Rowland, Michael Drozd, Oliver I Brown, Chew Cheng, Piruthivi Sukumar, Katherine I Bridge, Eylem Levelt, Marc A Bailey, Kathryn J Griffin, Mark T Kearney, Richard M Cubbon","doi":"10.1177/14791641261474099","DOIUrl":"10.1177/14791641261474099","url":null,"abstract":"Diabetes mellitus (DM) approximately doubles the risk of atherosclerotic cardiovascular disease (ASCVD) events, but the molecular basis is poorly understood. Using RNA-sequencing data from two arterial sites in >90 people with DM and >330 controls, we defined differentially expressed genes (DEGs) associated with DM. UK Biobank (UKB) was then used to corroborate that DEGs in their plasma protein form were differentially abundant in people with DM and associated with ASCVD events. 619 and 356 DEGs were associated with DM in the thoracic aorta and tibial artery, respectively. Of these, 22 were common to both arteries, all of which were directionally concordant. Of these, 5 were included in the UKB plasma proteomics dataset and we corroborated 4 (ACP5, LEFTY2, LILRA5 and PSME2) as showing concordant differential abundance in people with DM; all were associated with a range of incident ASCVD events. Addition of the 4 proteins to the SCORE2 and SCORE2-Diabetes risk models (for people without and with DM, respectively) improved the population-level discrimination, classification and calibration of these models. These data show that DM is associated with a distinct arterial gene expression profile, hits from which are associated with ASCVD events and add value to risk prediction.","PeriodicalId":93978,"journal":{"name":"Diabetes & vascular disease research","volume":"23 4","pages":"14791641261474099"},"PeriodicalIF":3.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13428926/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148655438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Skin autofluorescence may be a biomarker associated suboptimal glycemic control in pregnant women with gestational diabetes mellitus. 皮肤自身荧光可能是妊娠期糖尿病患者血糖控制不佳相关的生物标志物。

IF 3

Diabetes & vascular disease research Pub Date : 2026-07-01 Epub Date: 2026-07-28 DOI: 10.1177/14791641251398558

Manel Salsabil Alakrab, Dhekra Toumi, Ameni Selmi, Ahmed Hajji, Olfa Zoukar, Salwa Abid, Raja Faleh, Mohsen Kerkeni

{"title":"Skin autofluorescence may be a biomarker associated suboptimal glycemic control in pregnant women with gestational diabetes mellitus.","authors":"Manel Salsabil Alakrab, Dhekra Toumi, Ameni Selmi, Ahmed Hajji, Olfa Zoukar, Salwa Abid, Raja Faleh, Mohsen Kerkeni","doi":"10.1177/14791641251398558","DOIUrl":"10.1177/14791641251398558","url":null,"abstract":"BackgroundAdvanced glycation end products (AGEs) can be measured non-invasively through skin autofluorescence (SAF). Studies on SAF in gestational diabetes mellitus (GDM) remain limited. This study aims to evaluate SAF in Tunisian pregnant women with GDM and its association with the requirement for insulin therapy.MethodsA cross sectional study was conducted of 242 pregnant women who visited at the Monastir-Tunisia Center for Maternity. Screening for GDM was performed using the OGTT. 200 pregnant women were included in the study with and without GDM. We measured SAF using the AGE reader Mu device and the age-adjusted SAF-z score was calculated.ResultsHigher SAF levels and SAF-z scores were observed in pregnant women with GDM compared to healthy controls (2.1 ± 0.5 AU vs 1.9 ± 0.4 AU p < 0.001, 1.02 ± 0.9 vs 0.64 ± 0.7 p = 0.002, respectively). The ROC analysis revealed that an SAF >2.3 AU was the optimal cut-off point for predicting insulin therapy requirement with a sensitivity of 90.9% and a specificity of 69.7% (p < 0.001).ConclusionSAF was increased in GDM, and can be a biomarker associated suboptimal glycemic control in pregnant women with GDM. Our findings highlight the relevance of SAF measurement and suggest SAF monitoring during pregnancy.","PeriodicalId":93978,"journal":{"name":"Diabetes & vascular disease research","volume":"23 4","pages":"14791641251398558"},"PeriodicalIF":3.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13424518/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148611279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Serum albumin-enhanced screening: A triage strategy and predictive model for OGTT in community-managed patients with coronary heart disease. 血清白蛋白增强筛查：社区管理的冠心病患者OGTT的分诊策略和预测模型

IF 3

Diabetes & vascular disease research Pub Date : 2026-07-01 Epub Date: 2026-07-27 DOI: 10.1177/14791641261474034

Chumin Ni, XianWu Zhao, Xueying Liu, Kaixun Zhao, Weidai Zhang

{"title":"Serum albumin-enhanced screening: A triage strategy and predictive model for OGTT in community-managed patients with coronary heart disease.","authors":"Chumin Ni, XianWu Zhao, Xueying Liu, Kaixun Zhao, Weidai Zhang","doi":"10.1177/14791641261474034","DOIUrl":"10.1177/14791641261474034","url":null,"abstract":"BackgroundPatients with coronary heart disease (CHD) are at high risk of undiagnosed diabetes. Reliance on standard fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c) may lead to underdiagnosis, highlighting the need for optimized screening strategies.MethodsUsing data from the National Health and Nutrition Examination Survey (NHANES) cycles 2007-2016, we analyzed 287 patients with CHD and 8,904 non-CHD controls without pre-existing diabetes. A two-tier protocol was implemented, consisting of initial FPG/HbA1c screening followed by OGTT. A prediction model was derived to identify individuals at high risk for OGTT-dependent diabetes.ResultsPatients with CHD had a 3.4-fold higher weighted prevalence of newly diagnosed diabetes than controls (22.1% [95% CI, 16.5%-28.8%] vs. 6.5% [95% CI, 5.8%-7.2%]). Initial FPG/HbA1c screening missed 32 of 64 diabetes cases (50.0%), which were detectable only by OGTT. The albumin-enhanced model (HbA1c + FPG + albumin) demonstrated robust discriminatory capacity (AUC 0.823) and provided significant incremental value over the HbA1c + FPG model, with an integrated discrimination improvement of 0.0611 and net reclassification improvement of 0.1562 (both P<0.05).ConclusionSerum albumin is an adjunctive biomarker that enhances prediction. Our model may provide an effective triage strategy for targeting OGTT in high-risk individuals, enhancing screening efficiency.","PeriodicalId":93978,"journal":{"name":"Diabetes & vascular disease research","volume":"23 4","pages":"14791641261474034"},"PeriodicalIF":3.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13408058/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148611262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0